论文部分内容阅读
目的探讨不同剂量阿立哌唑治疗儿童Tourette综合征的长期疗效及安全性。方法选取2012年2月至2016年2月在首都儿科研究所附属儿童医院神经科门诊接受阿立派唑治疗并长期随访的Tourette综合征患儿(68例)为研究对象,根据药物剂量不同分为<10 mg/d剂量组和10~15 mg/d剂量组各34例,采用耶鲁综合抽动严重程度量表(YGTSS)对患儿抽动严重程度进行评价;同时对两组患儿的YGTSS评分、复发及不良反应情况进行对比。结果10~15 mg/d剂量组患儿的总有效率(97.1%)明显高于<10 mg/d剂量组(79.4%),差异有统计学意义(P<0.05);10~15mg/d剂量组治疗后的YGTSS评分明显低于<10 mg/d剂量组,差异有统计学意义(P<0.05);<10 mg/d剂量组患儿服药体重增加明显少于10~15 mg/d剂量组(P<0.05)。结论大剂量阿立哌唑对多巴胺D2受体阻滞剂耐药的Tourette综合征有效,但是大剂量阿立哌唑的不良反应高于小剂量组。
Objective To investigate the long-term efficacy and safety of different doses of aripiprazole in children with Tourette’s syndrome. Methods From February 2012 to February 2016, 68 children with Tourette’s syndrome (68 cases) receiving long-term follow-up and received alitrazol at the Children’s Hospital Neurology Clinic affiliated to the Capital Institute of Pediatrics were selected as study subjects. According to the dose of the drug, 34 patients in the dose of <10 mg / d and 10 mg / d of the dose of 15 mg were enrolled in this study. The severity of tics in children was assessed by Yale tic disorder severity scale (YGTSS). The YGTSS score, Recurrence and adverse reactions were compared. Results The total effective rate (97.1%) in 10-15 mg / d group was significantly higher than that in 10 mg / d (79.4%) group (P <0.05) The YGTSS score of the dose group was significantly lower than <10 mg / d, the difference was statistically significant (P <0.05); the weight gain of children <10 mg / d dose group was significantly less than 10 ~ 15 mg / d Dose group (P <0.05). Conclusions High-dose aripiprazole is effective in treating Tourette’s syndrome resistant to dopamine D2 blockers, but high-dose aripiprazole has higher adverse reactions than the low-dose group.